Evidence
Neuropathology. 2023 May 23. doi: 10.1111/neup.12912. Online ahead of print.
ABSTRACT
Spinal ependymoma with MYCN amplification is a newly recognized type of spinal ependymoma that is known to be associated with poor prognosis. Available studies on this relatively rare tumor type have observed that these tumors tend to disseminate along the spinal cord and behave aggressively with worse overall and progression-free survival compared to the other types of ependymoma. In this study, we describe the clinical and histopathological features of spinal ependymomas in a single institution cohort with emphasis on those with MYCN amplification.
PMID:37221449 | DOI:10.1111/neup.12912
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 2 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
MYCN amplification in spinal ependymoma: A five-year retrospective study
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
MYCN amplification in spinal ependymoma: A five-year retrospective study
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
MYCN amplification in spinal ependymoma: A five-year retrospective study
🌐 365 Days
VR Related Evidence Matrix
